OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
40
Results
Show all
Save search
Copy query
Show results for
Unknown
(40)
Publication Date
Release Date
2021
(7)
2017
(6)
2019
(4)
2015
(4)
2020
(3)
2018
(3)
2016
(3)
2025
(2)
2024
(2)
2022
(2)
2014
(2)
2012
(2)
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Not available
S-EPMC5070554
|
biostudies-literature
Cite
BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
Not available
S-EPMC3936197
|
biostudies-literature
Cite
Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.
Not available
S-EPMC5528370
|
biostudies-literature
Cite
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study.
Not available
S-EPMC5153255
|
biostudies-literature
Cite
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Not available
S-EPMC6567408
|
biostudies-literature
Cite
RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway.
Not available
S-EPMC4396491
|
biostudies-literature
Cite
Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.
Not available
S-EPMC5620144
|
biostudies-literature
Cite
Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
Not available
S-EPMC5503785
|
biostudies-literature
Cite
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
Not available
S-EPMC4766869
|
biostudies-literature
Cite
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Not available
S-EPMC8868006
|
biostudies-literature
Cite
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets